Subq vs IM doesn't matter — peptides are peptides; just inject wherever, they end up in the same place.

The injection-technique question doesn't get debated as much as dosing or stacking does, partly because it feels mechanical rather than pharmacological. The error is treating route as a deliverability question (where can I get the molecule into circulation?) rather than a pharmacology question (what does this route do to the molecule's plasma curve, tissue distribution, and effect spectrum?). For some peptides, route makes a substantial difference. For others, less. Pretending it's never relevant is the over-correction.

What route actually changes

Three pharmacokinetic dimensions move with route:

1. Absorption rate and peak plasma concentration. Subcutaneous (subq) absorption is slower than intramuscular (IM), with a lower peak and a flatter curve. IM absorption is faster, with a higher peak. Intranasal (IN) is faster still for some molecules, with rapid CNS partitioning via olfactory and trigeminal pathways. Oral has additional first-pass metabolism considerations.

2. Tissue distribution. Different routes deliver the molecule to different early-distribution compartments. Subq deposits the molecule in subcutaneous adipose tissue, with slow absorption into systemic circulation. IM deposits in muscle, which has higher blood flow and faster systemic distribution. IN delivers preferentially to forebrain via the olfactory pathway, with relatively less systemic exposure.

3. Effect spectrum. For some peptides, the effect profile actually shifts with route. The clearest example: the Manchenko 2010 Semax route-dissociation paper showed in rats that intraperitoneal Semax produced both nootropic and analgesic effects, while intranasal Semax produced a stronger nootropic effect but no analgesic effect at any dose tested. The route changes the effect spectrum, not just the timing or magnitude.

Where route matters most

Semax and Selank — intranasal is the clinical convention because the route partitions peptide preferentially to forebrain targets relevant for cognitive and anxiolytic effects, while bypassing peripheral / descending pathways that systemic injection would recruit. This is well-characterized in the Russian primary literature and replicated in mice (Vasileva 2020). Switching to subq or IM injection is not equivalent — it produces a different effect profile.

Ipamorelin and CJC-1295 (DAC) — subq is the standard route for both. The pharmacokinetic profile is well-characterized: subq absorption produces the expected GH-pulse augmentation pattern with a manageable peak. IM administration would produce a higher peak with potential differences in receptor saturation dynamics; there's no published evidence supporting IM use, and the community pattern is overwhelmingly subq.

MK-677 — oral. The molecule was specifically designed for oral bioavailability (ghrelin-receptor agonism with first-pass-tolerant pharmacokinetics). Injecting MK-677 doesn't make pharmacological sense and isn't a route the community uses.

Tesamorelin — subq specifically. The Falutz 2007 NEJM trial used subq dosing; visceral-fat reduction effects appear to depend on the subq pharmacokinetic profile. IM administration would alter the peak/trough relationship.

PT-141 (Bremelanotide) — both subq and intranasal have been studied. Subq (the FDA-approved Vyleesi formulation) gives ~100% bioavailability; intranasal gives ~50-60%, with substantially higher dose required to achieve equivalent plasma levels. The community pattern favors subq for this reason. Intranasal saw early Palatin Technologies development that was discontinued in favor of subq.

BPC-157 — the most-discussed route question in the recreational community. Practitioner-protocol convention strongly favors proximal-to-injury subq (1-3 cm from the tender point for soft-tissue indications), citing faster perceived onset. The rodent BPC-157 mechanistic evidence is on intraperitoneal / systemic dosing, so the "local subq superiority" claim is community-anecdotal rather than published. Oral BPC-157 is the alternative route for gut-symptom contexts; the community-pattern evidence supports oral for IBS-pattern complaints (verified across ~30 sources per the corpus community-pattern entries).

Where route matters less

For some peptides the route is less critical than the convention suggests:

• GHK-Cu — topical works for skin / hair indications; subq works for systemic indications. Both are documented; route choice depends on indication rather than being a pharmacological constraint per se.
• Epitalon — subq is the dominant route, but intranasal has been explored. The intermittent-cycle protocol makes pharmacokinetics less route-sensitive than continuous-dose protocols would.

The technique side

Beyond route choice, technique within a route matters in specific ways:

Subq injection depth and site rotation. Subcutaneous tissue depth varies substantially across body sites — abdomen ~1-2 cm, thigh ~1-2 cm, deltoid fat pad less. Using a needle too long for the site can result in IM rather than subq deposit (faster absorption, different curve). Site rotation matters for adipose tissue health on chronic dosing — daily injections in the same site can produce lipohypertrophy, which then alters absorption from that site.

Reconstitution and storage. Bacteriostatic water for reconstitution. Refrigeration. Most peptides have 28-30 day post-reconstitution stability under proper storage; exceeding this isn't a sterile issue but a potency issue.

Sterile technique. Alcohol the vial septum. Alcohol the injection site. Use a fresh needle for each draw (one needle for drawing, one for injection is the gold-standard practice). Skin infection from injection-site contamination is the most-reported avoidable adverse event in community use.

Intranasal technique. Spray volume, head position during spray, breath-coordination. Intranasal absorption depends on the molecule actually depositing on absorptive nasal mucosa rather than running out the front of the nose or down the throat. Heads-back-and-breathe-in is the right technique; spray-and-immediately-sniff-hard is the wrong technique.

Where the critic has a real point

For some peptides, the practical impact of route variation is modest. If you switch from subq abdomen to subq thigh for Ipamorelin, the pharmacokinetic difference is small enough that the community subjectively wouldn't notice. If you accidentally inject IM instead of subq for the GH-secretagogue stack, the higher peak will produce a slightly larger acute GH pulse but the overall protocol effect is broadly similar.

So "just inject anywhere" is wrong as a generic statement but is approximately true for some peptides at some doses.

Where the critic loses the thread

The leap from "for some peptides route variation produces modest differences" to "route doesn't matter generally" is the over-correction. The Semax / Selank intranasal convention is not a tradition — it's the route that produces the documented effect profile. Using subq instead would produce a different effect profile. Same for Tesamorelin (subq specifically), MK-677 (oral), PT-141 (subq for bioavailability).

The right framing: route is mechanism-specific. Read the peptide encyclopedia entry for the specific molecule before deciding route based on convenience. The encyclopedia entries on this site specify the documented routes for each peptide; the dossiers and decision guides treat route at the operational level for protocols that use them.